Hill-Rom Holdings, Inc. (NYSE:HRC) declared a quarterly dividend on Wednesday, July 15th, Zacks reports. Shareholders of record on Friday, September 18th will be paid a dividend of 0.22 per share by the medical technology company on Wednesday, September 30th. This represents a $0.88 dividend on an annualized basis and a yield of 1.04%. The ex-dividend date of this dividend is Thursday, September 17th.
Hill-Rom has raised its dividend payment by 23.5% over the last three years and has increased its dividend every year for the last 1 years. Hill-Rom has a payout ratio of 16.1% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Hill-Rom to earn $5.61 per share next year, which means the company should continue to be able to cover its $0.88 annual dividend with an expected future payout ratio of 15.7%.
HRC opened at $84.23 on Wednesday. The firm’s fifty day moving average is $95.18 and its two-hundred day moving average is $101.24. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.16 and a current ratio of 1.50. The firm has a market cap of $5.61 billion, a PE ratio of 27.17, a price-to-earnings-growth ratio of 2.71 and a beta of 0.59. Hill-Rom has a twelve month low of $72.29 and a twelve month high of $117.68.
Hill-Rom (NYSE:HRC) last posted its earnings results on Friday, July 31st. The medical technology company reported $1.95 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.46 by $0.49. The company had revenue of $767.50 million for the quarter, compared to analyst estimates of $749.39 million. Hill-Rom had a net margin of 7.05% and a return on equity of 25.48%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period last year, the business posted $1.23 earnings per share. Equities analysts forecast that Hill-Rom will post 5.45 EPS for the current fiscal year.
In other news, SVP Mary Kay Ladone sold 2,278 shares of Hill-Rom stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $110.00, for a total value of $250,580.00. Following the completion of the transaction, the senior vice president now owns 8,163 shares of the company’s stock, valued at approximately $897,930. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.65% of the company’s stock.
Several research firms have weighed in on HRC. Needham & Company LLC cut their target price on shares of Hill-Rom from $131.00 to $129.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Raymond James dropped their price objective on shares of Hill-Rom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Monday, August 3rd. Morgan Stanley dropped their price objective on shares of Hill-Rom from $123.00 to $112.00 and set an “overweight” rating on the stock in a report on Monday, August 3rd. Robert W. Baird started coverage on shares of Hill-Rom in a report on Tuesday, September 1st. They set an “outperform” rating and a $115.00 price objective on the stock. Finally, ValuEngine lowered shares of Hill-Rom from a “hold” rating to a “sell” rating in a report on Monday, August 3rd. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $122.71.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Featured Article: S&P 500 Index
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.